Key result
The combination of serum lipids PC (17:0/22:6) and ACar (17:3) yielded an area under the curve of 0.865 for the diagnosis of antiphospholipid syndrome.
Why the study?
To analyze the characteristics of lipid metabolism in the serum of women with antiphospholipid syndrome using untargeted lipidomics.
Can serum lipid markers identified by untargeted lipidomics accurately diagnose obstetric antiphospholipid syndrome?
Case-Control (n=40)
Can serum lipid markers identified by untargeted lipidomics accurately diagnose obstetric antiphospholipid syndrome?
Serum lipid markers PC (17:0/22:6) and ACar (17:3) show potential as diagnostic biomarkers for obstetric antiphospholipid syndrome.
Should not yet change obstetric APS workup; leaves open lipidomic biomarkers for diagnosis in larger validation studies.
This study used untargeted lipidomics to analyze the characteristics of lipid metabolism in the serum of women with antiphospholipid syndrome. Twenty female patients with APS and 20 healthy controls were recruited to this study. Untargeted lipidomics with liquid chromatography-tandem mass spectrometry was used to profile serum lipids. Correlation analyses were performed on the significant differential lipids. Least absolute shrinkage and selection operator (LASSO) regression and binary logistic regression analyses were performed to find possible biomarkers. Finally, receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic performance of biomarkers. The serum lipid profile of women with APS was significantly different from that of healthy controls. After statistical analysis and database matching, 12 lipids were found to be significantly different between the two groups, with the most obvious differences being triacylglycerols and phosphatidylcholines. LASSO regression and binary logistic regression models revealed that PC (17:0/22:6) and ACar (17:3) may be serum biomarkers of APS. ROC curve analysis shows that PC (17:0/22:6) and ACar (17:3) combined gave an area under the curve of 0.865 for the diagnosis of APS. PC (17:0/22:6) and ACar (17:3) could be used as biomarkers of APS.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2025) conducted a case-control in Antiphospholipid syndrome (n=40). Antiphospholipid syndrome vs. Healthy controls was evaluated on Diagnostic performance of combined PC (17:0/22:6) and ACar (17:3) for APS (AUC 0.865). The combination of serum lipids PC (17:0/22:6) and ACar (17:3) yielded an area under the curve of 0.865 for the diagnosis of antiphospholipid syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Journal of Proteome Research